[1] [1] ABU-RUSTUM N R, YASHAR C M, AREND R, et al. NCCN guidelines® insights: cervical cancer, version 1.2024[J]. J Natl Compr Canc Netw, 2023, 21(12): 1224-1233.

[2] [2] VOELKER R A. Cervical cancer screening[J]. JAMA, 2023, 330(20): 2030.

[3] [3] WENZEL H H B, OLTHOF E P, BEKKERS R L M, et al. Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis - a review[J]. Cancer Treat Rev, 2022, 102: 102311.

[4] [4] ZHENG X M, LI C P, ZHANG L F, et al. Combining intravoxel incoherent motion diffusion-weighted imaging and texture analysis for a nomogram to predict early treatment response to concurrent chemoradiotherapy in cervical cancer patients[J]. J Oncol, 2021, 2021: 9345353.

[5] [5] WENG D H, XIONG H H, ZHU C K, et al. Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial[J]. Front Med, 2023, 17(1): 93-104.

[6] [6] YANG J, MEAD-HARVEY C, POLEN-DE C, et al. Survival outcomes in patients with cervical cancer treated with open versus robotic radical hysterectomy: our surgical pathology interrogation[J]. Gynecol Oncol, 2020, 159(2): 373-380.

[7] [7] ZHANG Y, LIU L, ZHANG K Y, et al. Nomograms combining clinical and imaging parameters to predict recurrence and disease-free survival after concurrent chemoradiotherapy in patients with locally advanced cervical cancer[J]. Acad Radiol, 2023, 30(3): 499-508.

[8] [8] GAO S, DU S Y, LU Z M, et al. Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer[J]. Eur Radiol, 2020, 30(2): 1191-1201.

[9] [9] JHA A K, MITHUN S, SHERKHANE U B, et al. Systematic review and meta-analysis of prediction models used in cervical cancer[J]. Artif Intell Med, 2023, 139: 102549.

[10] [10] PASKEH M D A, MIRZAEI S, GHOLAMI M H, et al. Cervical cancer progression is regulated by SOX transcription factors: revealing signaling networks and therapeutic strategies[J]. Biomed Pharmacother, 2021, 144: 112335.

[11] [11] HU C C, LIU T Y, ZHANG W X, et al. miR-145 inhibits aerobic glycolysis and cell proliferation of cervical cancer by acting on MYC[J]. FASEB J, 2023, 37(4): e22839.

[12] [12] SHIH I L, YEN R F, CHEN C A, et al. PET/MRI in cervical cancer: associations between imaging biomarkers and tumor stage, disease progression, and overall survival[J]. J Magn Reson Imaging, 2021, 53(1): 305-318.

[13] [13] LI J Y, CAO Y J, LIU Y C, et al. Multiomics profiling reveals the benefits of gamma-delta () T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer[J]. J Immunother Cancer, 2024, 12(1): e008355.

[14] [14] HU Y H, XIE C Y, YANG H, et al. Assessment of intratumoral and peritumoral computed tomography radiomics for predicting pathological complete response to neoadjuvant chemoradiation in patients with esophageal squamous cell carcinoma[J]. JAMA Netw Open, 2020, 3(9): e2015927.

[15] [15] XIA T Y, ZHOU Z H, MENG X P, et al. Predicting microvascular invasion in hepatocellular carcinoma using CT-based radiomics model[J]. Radiology, 2023, 307(4): e222729.

[16] [16] CHEN M, COPLEY S J, VIOLA P, et al. Radiomics and artificial intelligence for precision medicine in lung cancer treatment[J]. Semin Cancer Biol, 2023, 93: 97-113.

[17] [17] YU Y F, HE Z F, OUYANG J, et al. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: a machine learning, multicenter study[J]. EBioMedicine, 2021, 69: 103460.

[18] [18] TONG H P, SUN J J, FANG J Q, et al. A machine learning model based on PET/CT radiomics and clinical characteristics predicts tumor immune profiles in non-small cell lung cancer: a retrospective multicohort study[J]. Front Immunol, 2022, 13: 859323.

[20] [20] FAN H Q, LUO Y L, GU F, et al. Artificial intelligence-based MRI radiomics and radiogenomics in glioma[J]. Cancer Imaging, 2024, 24(1): 36.

[21] [21] BERA K, BRAMAN N, GUPTA A, et al. Predicting cancer outcomes with radiomics and artificial intelligence in radiology[J]. Nat Rev Clin Oncol, 2022, 19(2): 132-146.

[22] [22] COSTA G, CAVINATO L, MASCI C, et al. Virtual biopsy for diagnosis of chemotherapy-associated liver injuries and steatohepatitis: a combined radiomic and clinical model in patients with colorectal liver metastases[J]. Cancers (Basel), 2021, 13(12): 3077.

[25] [25] FAROOQI A M, SAWALHA A, OMIDI S J, et al. Seizures and status epilepticus in anti-NMDA receptor encephalitis[J]. J Neurol, 2025, 272(1): 95.

[26] [26] ZHANG Z H, WAN X J, LEI X Y, et al. Intra- and peri-tumoral MRI radiomics features for preoperative lymph node metastasis prediction in early-stage cervical cancer[J]. Insights Imaging, 2023, 14(1): 65.

[27] [27] YU F L, HUANG X J, ZHOU D T, et al. Genetic, DNA methylation, and immune profile discrepancies between earlystage single primary lung cancer and synchronous multiple primary lung cancer[J]. Clin Epigenetics, 2023, 15(1): 4.

[29] [29] LEE S W, HONG J H, YU M N, et al. Serum conversion pattern of SCC-Ag levels between pre- and post-chemoradiotherapy predicts recurrence and metastasis in cervical cancer: a multi-institutional analysis[J]. Clin Exp Metastasis, 2021, 38(5): 467-474.

[30] [30] SHI L, LIU Y X, LI J Y, et al. Establishment of a risk stratification model based on the combination of post-treatment serum squamous cell carcinoma antigen levels and FIGO stage of cervical cancer for treatment and surveillance decisionmaking[J]. J Cancer Res Clin Oncol, 2023, 149(9): 5999-6007.